Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria
Delayed initiation of omalizumab treatment following the onset of urticaria symptoms is associated with an increased risk of relapse. Therefore, omalizumab treatment should be initiated promptly in eligible patients.
Authors
- Melike Ocak (ORCID: https://orcid.org/0000-0001-7841-4690)
- Bülent Enis Şekerel (ORCID: https://orcid.org/0000-0001-7402-6850)
- Bahri Can Duran (ORCID: https://orcid.org/0000-0002-3605-2676)
- Ümit Murat Şahiner (ORCID: https://orcid.org/0000-0003-0088-913X)
- Özge Soyer (ORCID: https://orcid.org/0000-0002-7444-251X)
- Canan Caka (ORCID: https://orcid.org/0000-0003-3459-6407)
Institutions
- Hacettepe University (TR)
Publication Details
- Journal
- Pediatric Allergy and Immunology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1111/pai.70216
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00